Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.63 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.56 |
| ▸ | DUT | P33316 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111880 | 0.87 | KIF11 (0.59) | KIF11KCNN4DUTTDP1TSHR | |
| SCHEMBL12264131 | 0.85 | KIF11 (0.74) | KIF11KCNN4DUTTDP1TSHR | |
| SCHEMBL12264133 | 0.81 | KIF11 (0.68) | KIF11KCNN4DUTTSHRALDH1A1 | |
| SCHEMBL16886979 | 0.81 | KCNN4 (0.60) | KIF11KCNN4DUTTDP1TSHR | |
| SCHEMBL17980741 | 0.81 | KIF11 (0.52) | KIF11KCNN4DUTALDH1A1MIF | |
| SCHEMBL12264129 | 0.80 | KIF11 (0.61) | KIF11KCNN4DUTMIF | |
| SCHEMBL147990 | 0.79 | KIF11 (0.65) | KIF11KCNN4DUTTDP1ALDH1A1 | |
| SCHEMBL29679194 | 0.79 | KIF11 (0.65) | KIF11KCNN4DUTTDP1TSHR | |
| SCHEMBL10675170 | 0.77 | KIF11 (0.63) | KIF11KCNN4DUTTSHRALDH1A1 | |
| SCHEMBL8961063 | 0.77 | KCNN4 (0.68) | KIF11KCNN4DUTTDP1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10711013-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2020-07-14 | — | — | US | disclosed |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2019-04-04 | — | — | US | disclosed |
| US-10118933-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2018-11-06 | — | — | US | disclosed |
| EP-3369732-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2018-09-05 | — | — | EP | disclosed |
| US-20170260206-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2017-09-14 | — | — | US | disclosed |
| WO-2007119511-A1 | CEPHEM COMPOUNDS AND USE AS ANTIMICROBIAL AGENTS | ASTELLAS PHARMA INC. (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-7192943-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-03-20 | — | — | US | disclosed |
| CN-1852715-A | Cephem compounds | ASTELLAS PHARMA INC (JP) | 2006-10-25 | — | — | CN | disclosed |
| US-20050096306-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-0625514-B1 | 2-Amino-pyrazin-5-carboxamid derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1999-08-25 | — | — | EP | disclosed |
| US-5420130-A | Adrenergic blocking agents | SYNTHELABO (FR) | 1995-05-30 | — | — | US | disclosed |
| EP-0625514-A1 | 2-Amino-pyrazin-5-carboxamid derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1994-11-23 | — | — | EP | disclosed |
| US-5210086-A | Adrenergic antagonists, urogenital disorders | SYNTHELABO (FR) | 1993-05-11 | — | — | US | disclosed |
| US-5164397-A | Hypotensive | SYNTHELABO (FR) | 1992-11-17 | — | — | US | disclosed |
| EP-0435749-A1 | Derivatives of 2-aminopyrimidine-4-carboxamide, their preparation and therapeutic use | SYNTHELABO (FR) | 1991-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260206-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | KIF11 3802/4885KCNN4 4566/4885DUT 1325/4885 |
| US-10118933-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | KIF11 3802/4885KCNN4 4566/4885DUT 1325/4885 |
| US-20050096306-A1 | Cephem compounds | CEP170, ASS1, C1S | KIF11 3237/4885KCNN4 2885/4885DUT 2646/4885 |
| US-10711013-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | KIF11 3802/4885KCNN4 4566/4885DUT 1325/4885 |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | KIF11 3802/4885KCNN4 4566/4885DUT 1325/4885 |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | KIF11 3802/4885KCNN4 4566/4885DUT 1325/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | KIF11 3802/4885KCNN4 4566/4885DUT 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.